for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Anixa Biosciences Inc

ANIX.OQ

Latest Trade

3.97USD

Change

0.00(0.00%)

Volume

7,019

Today's Range

3.75

 - 

4.04

52 Week Range

2.74

 - 

5.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Anixa Biosciences Provides Update On CAR-T Program

Dec 13 (Reuters) - Anixa Biosciences Inc <ANIX.O>::ANIXA BIOSCIENCES PROVIDES UPDATE ON CAR-T PROGRAM.ANIXA BIOSCIENCES- EXPERIMENTAL RESULTS SHOW EFFICACY OF CAR-T TECHNOLOGY AS OVARIAN CANCER TREATMENT COULD BE IMPROVED BY MORE GENETIC ENGINEERING.ANIXA BIOSCIENCES - DECISION HAS BEEN MADE TO OPTIMIZE CAR-T THERAPY AND FILE AN IND APPLICATION WITH US. FDA IN FUTURE.ANIXA BIOSCIENCES - OPTIMIZATION WORK ON CAR-T PROGRAM MAY TAKE EXTRA YEAR, RESULTING IN FILING OF IND IN LATE 2020, CLINICAL TRIALS TO START 2021.

Anixa Biosciences Announces Collaboration with Urology Centers of Alabama

Nov 22 (Reuters) - Anixa Biosciences Inc <ANIX.O>::ANIXA BIOSCIENCES - ANNOUNCED COLLABORATION WITH UROLOGY CENTERS OF ALABAMA (UCA) IN CCHEK EARLY PROSTATE CANCER DETECTION STUDY.

Anixa Biosciences says Co, Certain Current & Former Officers Entered Settlement Agreement With Co's Stockholder

Aug 27 (Reuters) - Anixa Biosciences Inc <ANIX.O>::ANIXA BIOSCIENCES - ON AUG 21, CO, CERTAIN OF ITS CURRENT & FORMER OFFICERS ENTERED SETTLEMENT AGREEMENT WITH STOCKHOLDER OF COMPANY.ANIXA BIOSCIENCES - SETTLEMENT AGREEMENT RESOLVES LAWSUIT BROUGHT DERIVATIVELY ON BEHALF OF CO IN DELAWARE COURT OF CHANCERY.ANIXA BIOSCIENCES INC - ALL OF CLAIMS ASSERTED IN DERIVATIVE ACTION WILL BE DISMISSED.

Anixa Biosciences Inc Files For Mixed Shelf Of Up To $100 Million – SEC Filing

June 11 (Reuters) - Anixa Biosciences Inc <ANIX.O>::ANIXA BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING.

Anixa Biosciences Announces Completion Of Pre-Sub Meeting With FDA

Dec 19 (Reuters) - Anixa Biosciences Inc <ANIX.O>::ANIXA BIOSCIENCES ANNOUNCES COMPLETION OF PRE-SUB MEETING WITH FDA FOR ITS CCHEK CANCER DIAGNOSTIC TEST.ANIXA BIOSCIENCES INC - ANNOUNCED THAT IT COMPLETED A PRE-SUBMISSION (PRE-SUB) MEETING WITH US FDA ON DECEMBER 17, 2018..ANIXA BIOSCIENCES INC - DISCUSSION FOCUSED ON USING CCHEK FOR PROSTATE CANCER TESTING, AS PROSTATE CANCER WILL BE FIRST COMMERCIAL APPLICATION..

Anixa Biosciences Files Pre-Submission And Requests Meeting With FDA

Oct 15 (Reuters) - Anixa Biosciences Inc <ANIX.O>::ANIXA BIOSCIENCES FILES PRE-SUBMISSION AND REQUESTS MEETING WITH FDA REGARDING CCHEK™ ARTIFICIAL INTELLIGENCE BASED CANCER DETECTION TECHNOLOGY.ANIXA BIOSCIENCES INC - REQUESTED A FACE-TO-FACE MEETING WITH FDA FOR DISCUSSION.

Itus Corp - Co Entered Into An At Market Issuance Sales Agreement With B. Riley FBR, Inc

March 27 (Reuters) - Itus Corp <ITUS.O>::ITUS CORP - ‍ON MARCH 27, CO ENTERED INTO AN AT MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY FBR, INC TO CREATE AN AT MARKET EQUITY PROGRAM​.ITUS CORP - CO MAY SELL UP TO 2.2 MILLION SHARES OF COMPANY'S COMMON STOCK FROM TIME TO TIME THROUGH AGENT, AS SALES AGENT - SEC FILING​.

Itus Corp Forms Alliance With Serametrix Corp

March 5 (Reuters) - Itus Corp <ITUS.O>::ITUS CORPORATION FORMS ALLIANCE WITH SERAMETRIX CORPORATION.‍ITUS, SERAMETRIX SIGNED AGREEMENT TO BRING CCHEK, CANCER DIAGNOSTIC TECHNOLOGY TO SERAMETRIX'S EXPERTISE IN IMMUNE MONITORING ASSAYS​.

Itus Corporation Terminates At-The-Market Offering

Dec 12 (Reuters) - Itus Corp <ITUS.O>::ITUS CORPORATION TERMINATES AT-THE-MARKET OFFERING.‍TERMINATED ITS AT-THE-MARKET EQUITY PROGRAM WITH B. RILEY FBR INC​.

Itus enters into 2-year collaboration agreement

Nov 22 (Reuters) - Itus Corp <ITUS.O>::Itus Corp - ‍on Nov 17, co, through unit entered into a 2 -year collaboration agreement with H. Lee Moffitt Cancer Center And Research Institute​.Itus - ‍ deal to advance toward human clinical testing car-t technology licensed by unit from Wistar Institute aimed initially at treating ovarian cancer​.Itus Corp says unit of co to pay Moffitt $1.16 million over two years for its efforts in collaboration - SEC filing.Itus Corp - unit to work with researchers at Moffitt to complete studies necessary to submit an IND application for technology with U.S. FDA​.Itus Corp - ‍first payment from unit to Moffitt to be paid upon execution of agreement, and subsequent installments to be paid periodically thereafter​.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up